Literature DB >> 17384923

[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

C Chapple.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17384923     DOI： 10.1007/s00120-007-1325-6

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  2 in total

1.  Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.

Authors:  Udo Jonas; Raymond R Rackley
Journal:  Eur Urol       Date:  2005-11-15       Impact factor: 20.096

2.  Solifenacin versus tolterodine--a head-to-head study: finally! But not final?

Authors:  David R Staskin; Roger R Dmochowski; Alan J Wein
Journal:  Curr Urol Rep       Date:  2005-11       Impact factor: 3.092
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.